Home › Companies › SAREPTA THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and SAREPTA THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated November 1, 2026.
Meeting of June 5, 2025: 8 items on SAREPTA THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025: 4 elected · 4 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore SAREPTA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are SAREPTA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard J. Barry | 64,757,685 | 9,565,547 | 60,768 | -- | 10,202,114 | 87% | Elected | — |
| Elect Director: M. Kathleen Behrens, Ph.D. | 69,004,024 | 5,336,943 | 43,033 | -- | 10,202,114 | 93% | Elected | — |
| Elect Director: Stephen L. Mayo, Ph.D. | 73,289,653 | 1,051,656 | 42,691 | -- | 10,202,114 | 99% | Elected | — |
| Elect Director: Claude Nicaise, M.D. | 71,006,475 | 3,334,914 | 42,611 | -- | 10,202,114 | 96% | Elected | — |
| 2. Advisory Vote to Approve Named Executive Officer Compensation | 72,144,292 | 2,176,998 | 62,710 | -- | 10,202,114 | 97% | Approved | — |
| 3. Amendment to the Company's 2018 Equity Incentive Plan | 71,084,947 | 3,248,699 | 50,354 | -- | 10,202,114 | 96% | Approved | — |
| 4. Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan | 73,725,724 | 629,170 | 29,106 | -- | 10,202,114 | 99.1% | Approved | — |
| 5. Ratification of KPMG as the Company's Independent Registered Public Accounting Firm | 80,588,115 | 3,875,497 | 122,502 | -- | -- | 95% | Approved | — |
Source: SAREPTA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.
Each item below shows how the 477 asset managers that disclosed a SAREPTA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: CLAUDE NICAISE, M.D.
SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Claude Nicaise, M.D.”): 71,006,475 for, 3,334,914 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class II for a term of two years.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,173,594 | 0 | 0 | 0 | For |
| Capital Group | 5,853,584 | 0 | 0 | 0 | For |
| BlackRock | 5,747,470 | 0 | 0 | 0 | For |
| AMCAP FUND | 2,658,367 | 0 | 0 | 0 | For |
| Fidelity | 2,260,022 | 0 | 0 | 0 | For |
| State Street | 1,867,371 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,364,241 | 0 | 0 | 0 | For |
| T. Rowe Price | 823,977 | 119,182 | 0 | 0 | Mixed |
| Charles Schwab | 646,649 | 0 | 0 | 0 | For |
| Aberdeen | 618,314 | 0 | 0 | 0 | For |
| Federated Hermes | 446,388 | 0 | 0 | 0 | For |
| JPMorgan | 312,145 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 311,365 | 0 | 0 | 0 | For |
| Jackson National | 302,710 | 0 | 0 | 0 | For |
| First Trust | 301,014 | 0 | 0 | 0 | For |
| Dimensional | 276,610 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 249,715 | 0 | 0 | 0 | For |
| TIAA | 244,427 | 0 | 0 | 0 | For |
| John Hancock | 244,287 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 214,218 | 0 | 0 | 0 | For |
| Equitable | 101,734 | 105,439 | 0 | 0 | Mixed |
| AIG/SunAmerica | 143,239 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 122,516 | 0 | 0 | 0 | For |
| Empower | 109,173 | 0 | 0 | 0 | For |
| Brighthouse | 83,854 | 0 | 18,186 | 0 | Mixed |
Fund voting reports, all 108 managers: 38,186,273 for, 302,007 against, 18,186 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 976,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 976,000 for.
Combines 4 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: M. KATHLEEN BEHRENS, PH.D.
SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: M. Kathleen Behrens, Ph.D.”): 69,004,024 for, 5,336,943 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class II for a term of two years.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,172,472 | 1,122 | 0 | 0 | For |
| Capital Group | 5,853,584 | 0 | 0 | 0 | For |
| BlackRock | 5,747,470 | 0 | 0 | 0 | For |
| AMCAP FUND | 2,658,367 | 0 | 0 | 0 | For |
| Fidelity | 2,260,022 | 0 | 0 | 0 | For |
| State Street | 1,867,282 | 89 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,364,241 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 943,159 | 0 | 0 | Against |
| Charles Schwab | 646,649 | 0 | 0 | 0 | For |
| Aberdeen | 618,314 | 0 | 0 | 0 | For |
| Federated Hermes | 446,388 | 0 | 0 | 0 | For |
| JPMorgan | 312,145 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 311,365 | 0 | 0 | 0 | For |
| Jackson National | 191,766 | 110,944 | 0 | 0 | Mixed |
| First Trust | 301,014 | 0 | 0 | 0 | For |
| Dimensional | 276,610 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 249,715 | 0 | 0 | 0 | For |
| TIAA | 244,427 | 0 | 0 | 0 | For |
| John Hancock | 244,287 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 214,218 | 0 | 0 | 0 | For |
| Equitable | 101,734 | 105,439 | 0 | 0 | Mixed |
| AIG/SunAmerica | 143,239 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 122,516 | 0 | 0 | 0 | For |
| Empower | 57,405 | 51,768 | 0 | 0 | Mixed |
| Brighthouse | 53,416 | 30,438 | 18,186 | 0 | Mixed |
Fund voting reports, all 108 managers: 36,996,696 for, 1,491,584 against, 18,186 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 976,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 976,000 for.
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: RICHARD J. BARRY
SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Richard J. Barry”): 64,757,685 for, 9,565,547 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class II for a term of two years.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,172,471 | 1,123 | 0 | 0 | For |
| Capital Group | 5,853,584 | 0 | 0 | 0 | For |
| BlackRock | 5,747,470 | 0 | 0 | 0 | For |
| AMCAP FUND | 2,658,367 | 0 | 0 | 0 | For |
| Fidelity | 2,260,022 | 0 | 0 | 0 | For |
| State Street | 6,074 | 1,861,297 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 1,364,241 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 943,159 | 0 | 0 | Against |
| Charles Schwab | 646,649 | 0 | 0 | 0 | For |
| Aberdeen | 618,314 | 0 | 0 | 0 | For |
| Federated Hermes | 446,388 | 0 | 0 | 0 | For |
| JPMorgan | 312,145 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 311,365 | 0 | 0 | 0 | For |
| Jackson National | 191,766 | 110,944 | 0 | 0 | Mixed |
| First Trust | 301,014 | 0 | 0 | 0 | For |
| Dimensional | 276,610 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 249,715 | 0 | 0 | 0 | For |
| TIAA | 244,427 | 0 | 0 | 0 | For |
| John Hancock | 244,287 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 214,218 | 0 | 0 | 0 | For |
| Equitable | 101,734 | 105,439 | 0 | 0 | Mixed |
| AIG/SunAmerica | 143,239 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 122,516 | 0 | 0 | 0 | For |
| Empower | 57,405 | 51,768 | 0 | 0 | Mixed |
| Brighthouse | 53,416 | 30,438 | 18,186 | 0 | Mixed |
Fund voting reports, all 108 managers: 34,850,505 for, 3,637,775 against, 18,186 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 976,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 976,000 for.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: STEPHEN L. MAYO, PH.D.
SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Stephen L. Mayo, Ph.D.”): 73,289,653 for, 1,051,656 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class II for a term of two years.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,173,594 | 0 | 0 | 0 | For |
| Capital Group | 5,853,584 | 0 | 0 | 0 | For |
| BlackRock | 5,747,470 | 0 | 0 | 0 | For |
| AMCAP FUND | 2,658,367 | 0 | 0 | 0 | For |
| Fidelity | 2,260,022 | 0 | 0 | 0 | For |
| State Street | 1,867,371 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,364,241 | 0 | 0 | 0 | For |
| T. Rowe Price | 823,977 | 119,182 | 0 | 0 | Mixed |
| Charles Schwab | 646,649 | 0 | 0 | 0 | For |
| Aberdeen | 618,314 | 0 | 0 | 0 | For |
| Federated Hermes | 446,388 | 0 | 0 | 0 | For |
| JPMorgan | 312,145 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 311,365 | 0 | 0 | 0 | For |
| Jackson National | 302,710 | 0 | 0 | 0 | For |
| First Trust | 301,014 | 0 | 0 | 0 | For |
| Dimensional | 276,610 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 249,715 | 0 | 0 | 0 | For |
| TIAA | 244,427 | 0 | 0 | 0 | For |
| John Hancock | 244,287 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 214,218 | 0 | 0 | 0 | For |
| Equitable | 101,734 | 105,439 | 0 | 0 | Mixed |
| AIG/SunAmerica | 143,239 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 122,516 | 0 | 0 | 0 | For |
| Empower | 109,173 | 0 | 0 | 0 | For |
| Brighthouse | 83,854 | 0 | 18,186 | 0 | Mixed |
Fund voting reports, all 108 managers: 38,197,273 for, 291,007 against, 18,186 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 976,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 976,000 for.
Combines 5 wordings of this item as funds reported it.
99.1% Approved · of votes cast
Description as filed by funds: APPROVE AN AMENDMENT TO THE AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON JUNE 27, 2016, AND AMENDED ON JUNE 6, 2019 AND ON JUNE 8, 2023) (THE "2016 ESPP") TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2016 ESPP BY 300,000 SHARES TO 1,700,000 SHARES
SAREPTA THERAPEUTICS INC.’s own tally for this item (“4. Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan”): 73,725,724 for, 629,170 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4: Amendment to the Company's Amended and Restated 2013 Employee Stock Purchase Plan The stockholders approved the 2016 ESPP Amendment.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of SAREPTA THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Amend Stock Compensation Plan” (2 managers, 4,033 for, 3 against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,173,594 | 0 | 0 | 0 | For |
| Capital Group | 5,853,584 | 0 | 0 | 0 | For |
| BlackRock | 5,747,470 | 0 | 0 | 0 | For |
| AMCAP FUND | 2,658,367 | 0 | 0 | 0 | For |
| Fidelity | 2,260,022 | 0 | 0 | 0 | For |
| State Street | 1,867,371 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,364,241 | 0 | 0 | 0 | For |
| T. Rowe Price | 943,159 | 0 | 0 | 0 | For |
| Charles Schwab | 646,649 | 0 | 0 | 0 | For |
| Aberdeen | 618,314 | 0 | 0 | 0 | For |
| Federated Hermes | 446,388 | 0 | 0 | 0 | For |
| JPMorgan | 312,145 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 311,365 | 0 | 0 | 0 | For |
| Jackson National | 302,710 | 0 | 0 | 0 | For |
| First Trust | 301,014 | 0 | 0 | 0 | For |
| Dimensional | 276,610 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 249,715 | 0 | 0 | 0 | For |
| TIAA | 244,427 | 0 | 0 | 0 | For |
| John Hancock | 244,287 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 214,218 | 0 | 0 | 0 | For |
| Equitable | 207,173 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 143,239 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 122,516 | 0 | 0 | 0 | For |
| Empower | 109,173 | 0 | 0 | 0 | For |
| Brighthouse | 83,854 | 18,186 | 0 | 0 | Mixed |
Fund voting reports, all 110 managers: 38,492,431 for, 18,186 against, 0 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 976,000 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 1,089 | 0 | 0 | 0 | For |
| VOISARD ASSET MANAGEMENT GROUP, INC. | 3 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 977,092 for.
Combines 4 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: APPROVE AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN (THE "2018 PLAN") TO INCREASE THE MAXIMUM AGGREGATE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED PURSUANT TO AWARDS GRANTED UNDER THE 2018 PLAN BY 4,300,000 SHARES TO 17,487,596 SHARES
SAREPTA THERAPEUTICS INC.’s own tally for this item (“3. Amendment to the Company's 2018 Equity Incentive Plan”): 71,084,947 for, 3,248,699 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Amendment to the Company's 2018 Equity Incentive Plan The stockholders approved the 2018 Plan Amendment.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 38,218,210 for, 236,388 against, 18,186 abstained, 39 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,173,594 | 0 | 0 | 0 | For |
| Capital Group | 5,853,584 | 0 | 0 | 0 | For |
| BlackRock | 5,747,470 | 0 | 0 | 0 | For |
| AMCAP FUND | 2,658,367 | 0 | 0 | 0 | For |
| Fidelity | 2,075,086 | 184,936 | 0 | 0 | Mixed |
| State Street | 1,867,329 | 42 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,364,241 | 0 | 0 | 0 | For |
| T. Rowe Price | 943,159 | 0 | 0 | 0 | For |
| Charles Schwab | 646,649 | 0 | 0 | 0 | For |
| Aberdeen | 618,314 | 0 | 0 | 0 | For |
| Federated Hermes | 446,388 | 0 | 0 | 0 | For |
| JPMorgan | 312,145 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 311,365 | 0 | 0 | 0 | For |
| Jackson National | 302,710 | 0 | 0 | 0 | For |
| First Trust | 301,014 | 0 | 0 | 0 | For |
| Dimensional | 276,610 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 249,715 | 0 | 0 | 0 | For |
| TIAA | 244,427 | 0 | 0 | 0 | For |
| John Hancock | 244,287 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 214,218 | 0 | 0 | 0 | For |
| Equitable | 207,173 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 143,239 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 122,516 | 0 | 0 | 0 | For |
| Brighthouse | 83,854 | 0 | 18,186 | 0 | Mixed |
| Voya | 96,032 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.
Combines 14 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION
SAREPTA THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote to Approve Named Executive Officer Compensation”): 72,144,292 for, 2,176,998 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2024.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,173,594 | 0 | 0 | 0 | For |
| Capital Group | 5,853,584 | 0 | 0 | 0 | For |
| BlackRock | 5,747,470 | 0 | 0 | 0 | For |
| AMCAP FUND | 2,658,367 | 0 | 0 | 0 | For |
| Fidelity | 2,260,022 | 0 | 0 | 0 | For |
| State Street | 1,867,371 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,364,241 | 0 | 0 | 0 | For |
| T. Rowe Price | 943,159 | 0 | 0 | 0 | For |
| Charles Schwab | 646,649 | 0 | 0 | 0 | For |
| Aberdeen | 618,314 | 0 | 0 | 0 | For |
| Federated Hermes | 446,388 | 0 | 0 | 0 | For |
| JPMorgan | 312,145 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 311,365 | 0 | 0 | 0 | For |
| Jackson National | 302,710 | 0 | 0 | 0 | For |
| First Trust | 301,014 | 0 | 0 | 0 | For |
| Dimensional | 276,610 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 249,715 | 0 | 0 | 0 | For |
| TIAA | 244,427 | 0 | 0 | 0 | For |
| John Hancock | 244,287 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 214,218 | 0 | 0 | 0 | For |
| Equitable | 207,173 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 143,239 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 122,516 | 0 | 0 | 0 | For |
| Empower | 109,173 | 0 | 0 | 0 | For |
| Brighthouse | 83,854 | 0 | 18,186 | 0 | Mixed |
Fund voting reports, all 110 managers: 38,464,340 for, 28,091 against, 18,186 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,009,911 | 0 | 0 | 0 | For |
| State Street | 3,843,582 | 0 | 0 | 0 | For |
| BlackRock | 3,258,704 | 548 | 0 | 0 | For |
| Wellington | 2,881,677 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 2,800,000 | 0 | 0 | 0 | For |
| Janus Henderson | 2,465,732 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,322,489 | 0 | 0 | 0 | For |
| JPMorgan | 2,010,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,880,266 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,816,659 | 0 | 0 | 0 | For |
| Camber Capital Management LP | 1,000,000 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 976,000 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 899,731 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 700,617 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 667,042 | 0 | 0 | 0 | For |
| Charles Schwab | 658,118 | 0 | 0 | 0 | For |
| Aberdeen | 650,279 | 0 | 0 | 0 | For |
| Northern Trust | 643,694 | 0 | 0 | 0 | For |
| Federated Hermes | 514,471 | 0 | 0 | 0 | For |
| John Hancock | 367,138 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 332,361 | 0 | 0 | 0 | For |
| EAGLE ASSET MANAGEMENT INC | 324,695 | 0 | 0 | 0 | For |
| Fiera Capital Corp | 300,547 | 0 | 0 | 0 | For |
| Amundi | 0 | 285,874 | 0 | 0 | Against |
| Brandywine Global Investment Management, LLC | 0 | 261,547 | 0 | 0 | Against |
Institutional-manager reports, all 390 managers: 47,138,357 for, 1,476,418 against, 2,969 abstained, 1,622 not voted. Showing the 25 largest; see all in the interactive database.
Combines 4 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT YEAR ENDING DECEMBER 31, 2025
SAREPTA THERAPEUTICS INC.’s own tally for this item (“5. Ratification of KPMG as the Company's Independent Registered Public Accounting Firm”): 80,588,115 for, 3,875,497 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 5: Ratification of KPMG as the Company's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2025.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,172,472 | 1,122 | 0 | 0 | For |
| Capital Group | 5,853,584 | 0 | 0 | 0 | For |
| BlackRock | 5,747,470 | 0 | 0 | 0 | For |
| AMCAP FUND | 2,658,367 | 0 | 0 | 0 | For |
| Fidelity | 2,260,022 | 0 | 0 | 0 | For |
| State Street | 1,866,769 | 602 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,364,241 | 0 | 0 | 0 | For |
| T. Rowe Price | 943,159 | 0 | 0 | 0 | For |
| Charles Schwab | 646,649 | 0 | 0 | 0 | For |
| Aberdeen | 618,314 | 0 | 0 | 0 | For |
| Federated Hermes | 446,388 | 0 | 0 | 0 | For |
| JPMorgan | 312,145 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 311,365 | 0 | 0 | 0 | For |
| Jackson National | 302,710 | 0 | 0 | 0 | For |
| First Trust | 301,014 | 0 | 0 | 0 | For |
| Dimensional | 276,610 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 249,715 | 0 | 0 | 0 | For |
| TIAA | 244,427 | 0 | 0 | 0 | For |
| John Hancock | 244,287 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 214,218 | 0 | 0 | 0 | For |
| Equitable | 207,173 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 143,239 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 122,516 | 0 | 0 | 0 | For |
| Empower | 109,173 | 0 | 0 | 0 | For |
| Brighthouse | 83,854 | 0 | 18,186 | 0 | Mixed |
Fund voting reports, all 110 managers: 38,397,618 for, 94,818 against, 18,186 abstained, 39 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 976,000 | 0 | 0 | 0 | For |
| VOISARD ASSET MANAGEMENT GROUP, INC. | 3 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 976,003 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 98,254,898 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.37% |
| 2 | Capital Group | 5.96% |
| 3 | BlackRock | 5.85% |
| 4 | AMCAP FUND | 2.71% |
| 5 | Fidelity | 2.30% |
| 6 | State Street | 1.90% |
| 7 | JANUS INVESTMENT FUND | 1.39% |
| 8 | T. Rowe Price | 0.96% |
| 9 | Charles Schwab | 0.66% |
| 10 | Aberdeen | 0.63% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 9.17% |
| 2 | State Street | 3.91% |
| 3 | BlackRock | 3.32% |
| 4 | Wellington | 2.93% |
| 5 | EcoR1 Capital, LLC | 2.85% |
| 6 | Janus Henderson | 2.51% |
| 7 | Avoro Capital Advisors LLC | 2.36% |
| 8 | JPMorgan | 2.05% |
| 9 | T. Rowe Price | 1.91% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.85% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Shares Issued and Outstanding 4/8/2025 | 100.00% | DEF14A |
| BlackRock | 10.08% | 13F |
| Capital International Investors | 9.05% | DEF14A |
| The Vanguard Group | 8.97% | DEF14A |
| AQR Capital Management, LLC | 8.25% | 13G |
| Vanguard Portfolio Management | 6.87% | 13G |
| State Street | 4.14% | 13F |
| Richard J. Barry | 3.29% | DEF14A |
| Wellington Management | 2.69% | 13F |
| Douglas S. Ingram | 2.64% | DEF14A |
Percentages above are of 98,254,898 shares outstanding, as reported by SAREPTA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SAREPTA THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.
At SAREPTA THERAPEUTICS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 477 asset managers reported how they voted on 8 ballot items in their SEC Form N-PX filings, covering 3,760 separate fund positions. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION — SAREPTA THERAPEUTICS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: SAREPTA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.
SAREPTA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.